Gosset Ownership
Private
Employees
~21
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
ASC Therapeutics General Information
ASC Therapeutics has initiated a Phase I/IIa clinical trial of its lead candidate ASC618 (AAV-based gene therapy) for hemophilia A. The company’s allogeneic cell therapy program ASC930 is in Phase 2 trials targeting acute steroid-refractory graft-versus-host disease. Preclinical programs include therapies for hemophilia B and beta-thalassemia. Early clinical data suggest potential advantages such as lower dosing requirements and improved durability over first-generation therapies
Contact Information
Primary Industry
Biotech
Corporate Office
Milpitas, California
United States
United States
Drug Pipeline
ASC618
Phase 1Key Partnerships
University of Massachusetts, University of Pennsylvania, Stanford University, Emory University, Shantou University Medical College Hospital & Peking University Shenzhen Hospital
ASC Therapeutics Funding
No funding data available
To view ASC Therapeutics's complete valuation and funding history, request access »